XTL Biopharmaceuticals Ltd. (XTLB)
NASDAQ: XTLB · IEX Real-Time Price · USD
2.810
+0.110 (4.07%)
At close: Mar 28, 2024, 4:00 PM
2.720
-0.090 (-3.20%)
After-hours: Mar 28, 2024, 7:47 PM EDT

XTL Biopharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 2022202120202019201820172016201520142013 2012 - 2004
Cash & Equivalents
2.092.973.634.463.263.292.023.822.162.89
Upgrade
Short-Term Investments
1.633.162.412.274.872.810.410.2501.28
Upgrade
Cash & Cash Equivalents
3.726.136.046.738.126.092.434.072.164.17
Upgrade
Cash Growth
-39.27%1.41%-10.20%-17.16%33.28%150.47%-40.19%88.42%-48.16%25.75%
Upgrade
Receivables
0000000.320.20.440.6
Upgrade
Inventory
0000000000.3
Upgrade
Other Current Assets
0.090.110.080.10.070.110000.02
Upgrade
Total Current Assets
3.816.246.126.838.26.212.754.272.65.09
Upgrade
Property, Plant & Equipment
0000000.010.010.020.06
Upgrade
Goodwill and Intangibles
0.380.380.380.380.380.380.251.042.52.87
Upgrade
Other Long-Term Assets
00000000.010.530
Upgrade
Total Long-Term Assets
0.380.380.380.380.380.380.261.063.052.93
Upgrade
Total Assets
4.196.626.57.218.586.593.025.325.648.02
Upgrade
Accounts Payable
0.190.230.250.230.250.30.330.440.521.22
Upgrade
Total Current Liabilities
-----0.30.330.440.521.22
Upgrade
Other Long-Term Liabilities
-----2.67000.450.01
Upgrade
Total Long-Term Liabilities
-----2.67000.450.01
Upgrade
Total Liabilities
0.191.292.890.71.32.970.330.440.971.23
Upgrade
Retained Earnings
-156.47-155.13-155.61-152.7-151.94-155.65-154.9-152.49-148.32-146.07
Upgrade
Comprehensive Income
000000.050.16000
Upgrade
Shareholders' Equity
45.333.616.527.273.622.694.894.666.27
Upgrade
Net Cash / Debt
3.726.136.046.738.126.092.434.072.164.17
Upgrade
Net Cash / Debt Growth
-39.27%1.41%-10.20%-17.16%33.28%150.47%-40.19%88.42%-48.16%25.75%
Upgrade
Net Cash Per Share
0.010.010.010.010.020.010.010.020.010.09
Upgrade
Working Capital
-----5.912.423.832.083.87
Upgrade
Book Value Per Share
0.731.000.701.271.410.770.981.852.0214.01
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).